Therapeutic immunization strategies for the control of HIV-1

References

• Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853–860 (1998).
   PubMed Web of Science ®Google Scholar
• Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science 305, 205–208 (2004).
   PubMed Web of Science ®Google Scholar
• McMichael A, Rowland-Jones S. Cellular immune responses to HIV. Nature 410, 980–987 (2001).
   PubMed Web of Science ®Google Scholar
• Schmitz JE, Kuroda MJ, Santra S et al. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J. Virol. 77, 2165–2173 (2003).
   PubMed Web of Science ®Google Scholar
• Douek DC, Brenchley JM, Betts MR et al. HIV preferentially infects HIV-specific CD4+ T-cells. Nature 417, 95–98 (2002).
   PubMed Web of Science ®Google Scholar
• McNeil AC, Shupert WL, Iyasere CA et al. High-level HIV-1 viremia suppresses viral antigen-specific CD4+ T-cell proliferation. Proc. Natl Acad. Sci. USA 98, 13878–13883 (2001).
   PubMed Web of Science ®Google Scholar
• Migueles SA, Laborico AC, Shupert WL et al. HIV-specific CD8+ T-cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nature Immunol. 3, 1061–1068 (2002).
   PubMed Web of Science ®Google Scholar
• Phillips R, Rowland-Jones S, Nixon D et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T-cell recognition. Nature 354, 453–459 (1991).
   PubMed Web of Science ®Google Scholar
• Ogg GS, Jin X, Bonhoeffer S et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T-lymphocytes after combination antiretroviral therapy. J. Virol. 73, 797–800 (1999).
   PubMed Web of Science ®Google Scholar
• Pitcher C, Quittner C, Peterson D et al. HIV-1-specific CD4+ T-cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Med. 5, 518–525 (1999).
   PubMed Web of Science ®Google Scholar
• Oxenius A, Price DA, Gunthard HF et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc. Natl Acad. Sci. USA 99, 13747–13752 (2002).
   PubMed Web of Science ®Google Scholar
• Davenport MP, Ribeiro RM, Perelson AS. Kinetics of virus-specific CD8+ T-cells and the control of human immunodeficiency virus infection. J. Virol. 78, 10096–10103 (2004).
   PubMedGoogle Scholar
• Rosenberg ES, Billingsley JM, Caliendo AM et al. Vigorous HIV-1-specific CD4+ T-cell responses associated with control of viremia. Science 278, 1447–1450 (1997).
   PubMed Web of Science ®Google Scholar
• Younes S, Yassine-Diab B, Dumont A et al. HIV-1 viremia prevents the establishment of interleukin-2-producing HIV-specific memory CD4+ T-cells endowed with proliferative capacity. J. Exp. Med. 198, 1909–1922 (2003).
   PubMed Web of Science ®Google Scholar
• Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A. Presence of HIV-1 gag-specific IFN-γ+IL-2+ and CD28+IL-2+ CD4 T-cell responses is associated with nonprogression in HIV-1 infection. J. Immunol. 169, 6376–6385 (2002).
   PubMed Web of Science ®Google Scholar
• Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T-cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103, 966–972 (2004).
   PubMedGoogle Scholar
• Tryniszewska E, Nacsa J, Lewis MG et al. Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J. Immunol. 169, 5347–5357 (2002).
   PubMed Web of Science ®Google Scholar
• Hel Z, Venzon D, Poudyal M et al. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nature Med. 6, 1140–1146 (2000).
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Gabrilovich DI, Varga G et al. Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells. J. Virol. 75, 7621–7628 (2001).
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Trocio J, Xu J et al. Control of viral rebound through therapeutic immunization with DermaVir®. AIDS 19, 35–43 (2005).
   PubMed Web of Science ®Google Scholar
• Lu W, Wu X, Lu Y, Guo W, Andrieu J. Therapeutic dendritic-cell vaccine for simian AIDS. Nature Med. 9, 27–32 (2003).
   PubMed Web of Science ®Google Scholar
• Redfield R, Birx D, Ketter N et al. A Phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N. Engl. J. Med. 324, 1677–1684 (1991).
   PubMed Web of Science ®Google Scholar
• Birx D, Loomis-Price L, Aronson N et al. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. J. Infect. Dis. 181, 881–889 (2000).
   PubMed Web of Science ®Google Scholar
• Kundu S, Katzenstein D, Moses L, Merigan T. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. Proc. Natl Acad. Sci. USA 89, 11204–11208 (1992).
   PubMedGoogle Scholar
• Goebel F, Mannhalter J, Belshe R et al. Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group. AIDS 13, 1461–1468 (1999).
   PubMed Web of Science ®Google Scholar
• Veenstra J, Williams I, Colebunders R et al. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. J. Infect. Dis. 174, 862–866 (1996).
   PubMed Web of Science ®Google Scholar
• Kelleher A, Roggensack M, Jaramillo A et al. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. AIDS 12, 175–182 (1998).
   PubMedGoogle Scholar
• Lindenburg CEA, Stolte I, Langendam MW et al. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine 20, 2343–2347 (2002).
   PubMed Web of Science ®Google Scholar
• Moss R, Giermakowska W, Savary J et al. A primer on HIV Type 1-specific immune function and REMUNE. AIDS Res. Hum. Retroviruses 14, S167–S175 (1998).
   Google Scholar
• Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S; for the 806 Investigator Team. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 106/L CD4 cell counts: a randomized controlled trial. JAMA 284, 2193–2202 (2000).
   PubMed Web of Science ®Google Scholar
• Robbins GK, Addo MM, Troung H et al. Augmentation of HIV-1-specific T-helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS 17, 1121–1126 (2003).
   PubMed Web of Science ®Google Scholar
• Kinloch S, Perrin L, Hoen B et al. Evaluation of two therapeutic HIV vaccination regimens in HAART-treated primary HIV infection subjects following analytical treatment interruption: QUEST PROB3005, a randomized, placebo-controlled study. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 8–11 February 2004 (Abstract 168).
   Google Scholar
• Samri A, Lampe F, Kinloch de Loes S et al. Relative effects of therapeutic immunisation and discontinuation of ART on HIV-1-specific CD4 and CD8 T-cells producing interferon-γ in ART-treated acutely infected subjects (QUEST Study). 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22–25 February 2005 (Abstract 524).
   Google Scholar
• Oxenius A, Price DA, Easterbrook PJ et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T-lymphocytes. Proc. Natl Acad. Sci. USA 97, 3382–3387 (2000).
   PubMed Web of Science ®Google Scholar
• McConkey S, Reece W, Moorthy V et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Med. 9, 729–735 (2003).
   PubMed Web of Science ®Google Scholar
• Mwau M, Cebere I, Sutton J et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85, 911–919 (2004).
   PubMed Web of Science ®Google Scholar
• MacGregor R, Boyer J, Ugen K et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus Type 1 infection: safety and host response. J. Infect. Dis. 178, 92–100 (1998).
   PubMed Web of Science ®Google Scholar
• Calarota S, Bratt G, Nordlund S et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351, 1320–1325 (1998).
   PubMed Web of Science ®Google Scholar
• Dorrell L, Yang H, Iversen A et al. Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/polyepitope DNA vaccine. AIDS (2005) (In Press).
   PubMedGoogle Scholar
• Wilson C, Livingston B, MaWhinney S et al. Immunogenicity of a multi-epitope-based DNA vaccine in HIV-1-infected subjects receiving potent antiretroviral therapy. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22–25 February 2005 (Abstract 527).
   Google Scholar
• Radaelli A, Nacsa J, Tsai W-P et al. Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251. Virology 312, 181–195 (2003).
   PubMedGoogle Scholar
• Dorrell L, Yang H, Ondondo B et al. Therapeutic immunisation with MVA.HIVA, a recombinant modified vaccinia virus Ankara/HIV-1 gag-polyepitope vaccine, in HIV-1-infected subjects receiving HAART. Keystone Symposia – HIV Vaccines: Current challenges and Future Prospects (X8). Banff, Alberta, Canada, 9–15 April 2005 (Abstract 147).
   Google Scholar
• Guimarães-Walker A, Mackie N, McMichael A et al. Priming with a candidate HIV-1 clade A DNA vaccine followed by booster with HIV-1 clade A MVA vaccine in volunteers at low risk of HIV infection. AIDS Vaccine 04. Lausanne, Switzerland, 30 August–1 September 2004 (Abstract 55).
   Google Scholar
• McMichael A. A boost for MVA. Keystone Symposia – HIV Vaccines: Current challenges and Future Prospects (X8). Banff, Alberta, Canada, 9–15 April 2005 (Abstract 025).
   Google Scholar
• Clements-Mann M-L, Weinhold K, Matthews T. Immune responses to human immunodeficiency virus Type 1 (HIV-1) induced by canarypox expressing HIV-1 MN gp120, HIV-1 SF2 recombinant gp120, or both vaccines in seronegative adults. J. Infect. Dis. 177, 1230–1246 (1998).
   PubMed Web of Science ®Google Scholar
• Belshe R, Stevens C, Gorse G. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a Phase II study in higher- and lower-risk volunteers. J. Infect. Dis. 183, 1343–1352 (2001).
   PubMed Web of Science ®Google Scholar
• Tubiana R, Carcelain G, Vray M et al. Therapeutic vaccination with ALVAC-HIV vCP1433: a recombinant canarypox vaccine in chronically HIV-1 infected patients treated with HAART: VACCITER (ANRS 094). 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 10–14 February 2003 (Abstract 61).
   Google Scholar
• Levy Y, Gahery-Segard H, Durier C et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 19, 279–286 (2005).
   PubMed Web of Science ®Google Scholar
• Kilby J, Wang R, Mildvan D et al. A Phase II randomized, partially blinded trial of antiretroviral therapy, HIV-specific immunizations, and IL-2 cycles to promote efficient control of viral replication (ACTG A5024). 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22–25 February 2005 (Abstract 525).
   Google Scholar
• Jin X, Ramanathan M Jr, Barsoum S et al. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J. Virol. 76, 2206–2216 (2002).
   PubMedGoogle Scholar
• Markowitz M, Jin X, Hurley A et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus Type 1 infection, with or without adjunctive vaccination. J. Infect. Dis. 186(5), 634–643 (2002).
   PubMed Web of Science ®Google Scholar
• Cosma A, Nagaraj R, Buhler S et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22, 21–29 (2003).
   PubMed Web of Science ®Google Scholar
• Harrer E, Bäuerle M, Ferstl B et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir. Ther. 10, 285–300 (2005).
   PubMed Web of Science ®Google Scholar
• Cooper D, Workman C, Puls R et al. Randomized, placebo-controlled, Phase 1/2a evaluation of the safety, biological activity and antiretroviral properties of an avipox virus vaccine expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 8–11 February 2004 (Abstract 169).
   Google Scholar
• Kundu S, Engleman E, Benike C. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res. Hum. Retroviruses 14, 551–560 (1998).
   PubMed Web of Science ®Google Scholar
• Garcia F, Lejeune M, Climent N et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J. Infect. Dis. 191, 1680–1685 (2005).
   PubMed Web of Science ®Google Scholar
• Lu W, Arraes LC, Ferreira WT, Andrieu J-M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nature Med. 10, 1359–1365 (2004).
   PubMed Web of Science ®Google Scholar
• Felber B, von Gegerfelt A, Rosati M et al. Control of viremia after antiretroviral treatment and therapeutic vaccination with novel forms of DNA vaccines in chronically SIVmac251-infected macaques. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22–25 February 2005 (Abstract 132).
   Google Scholar
• Boyer J, Calarota S, Parkinson R et al. Dramatic induction of antigen-specific immune responses and effects on viral rebound analysed in a novel chronic SIV infection treatment model by optimised SIV DNA antigens + IL-12 adjuvant vaccine. Keystone Symposia – HIV Vaccines: Current Challenges and Future Prospects (X8). Banff, Alberta, Canada, 9–15 April 2005 (Abstract 122).
   Google Scholar
• Yu Q, Yue E, Kovacs C, Tartaglia J, Ostrowski M. Expansion of HIV-1-specific memory CTL responses by dendritic cells infected with CD154(CD40L)-expressing ALVAC virus: towards the development of molecular adjuvants for HIV-1 vaccines. Keystone Symposia – HIV Vaccines: Current Challenges and Future Prospects (X8). Banff, Alberta, Canada, 9–15 April 2005 (Abstract 444).
   Google Scholar